{"analyses":[{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.63","groupDescription":"Emotional functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6063","paramType":"Odds Ratio (OR)","paramValue":"1.11","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.29","groupDescription":"Emotional functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5739","paramType":"Odds Ratio (OR)","paramValue":"0.90","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupDescription":"Emotional functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3792","paramType":"Odds Ratio (OR)","paramValue":"0.84","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.73","groupDescription":"Emotional functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6022","paramType":"Odds Ratio (OR)","paramValue":"1.12","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.49","groupDescription":"Emotional functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7893","paramType":"Odds Ratio (OR)","paramValue":"0.94","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.22","groupDescription":"Emotional functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2125","paramType":"Odds Ratio (OR)","paramValue":"0.71","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","groupDescription":"Emotional functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9661","paramType":"Odds Ratio (OR)","paramValue":"1.01","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.32","groupDescription":"Emotional functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4299","paramType":"Odds Ratio (OR)","paramValue":"0.83","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.36","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupDescription":"Emotional functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1542","paramType":"Odds Ratio (OR)","paramValue":"0.65","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"1.04","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.76","groupDescription":"Emotional functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0363","paramType":"Odds Ratio (OR)","paramValue":"2.65","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.93","groupDescription":"Emotional functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0814","paramType":"Odds Ratio (OR)","paramValue":"2.75","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"38.00","groupDescription":"Emotional functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1915","paramType":"Odds Ratio (OR)","paramValue":"4.03","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-4.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100.00","groupDescription":"Emotional functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3173","paramType":"Difference in Proportion of Responders","paramValue":"66.67","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.35","groupDescription":"Physical functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9818","paramType":"Odds Ratio (OR)","paramValue":"1.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.45","groupDescription":"Physical functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6263","paramType":"Odds Ratio (OR)","paramValue":"1.08","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.40","groupDescription":"Physical functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9407","paramType":"Odds Ratio (OR)","paramValue":"1.01","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.39","groupDescription":"Physical functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7700","paramType":"Odds Ratio (OR)","paramValue":"0.94","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.45","groupDescription":"Physical functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8458","paramType":"Odds Ratio (OR)","paramValue":"0.96","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.46","groupDescription":"Physical functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7028","paramType":"Odds Ratio (OR)","paramValue":"0.91","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.83","groupDescription":"Physical functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1391","paramType":"Odds Ratio (OR)","paramValue":"1.30","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.62","groupDescription":"Physical functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8002","paramType":"Odds Ratio (OR)","paramValue":"1.06","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.68","groupDescription":"Physical functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9751","paramType":"Odds Ratio (OR)","paramValue":"1.01","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.78","groupDescription":"Physical functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3811","paramType":"Odds Ratio (OR)","paramValue":"1.37","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.90","groupDescription":"Physical functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3950","paramType":"Odds Ratio (OR)","paramValue":"1.51","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.12","groupDescription":"Physical functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8993","paramType":"Odds Ratio (OR)","paramValue":"0.89","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-23.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100.00","groupDescription":"Physical functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified","nonInferiorityType":"SUPERIORITY","pValue":"0.3173","paramType":"Difference in Proportion of Responders","paramValue":"50.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupDescription":"Global health status/QoL, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5988","paramType":"Odds Ratio (OR)","paramValue":"0.92","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.34","groupDescription":"Global health status/QoL, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8859","paramType":"Odds Ratio (OR)","paramValue":"0.98","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","groupDescription":"Global health status/QoL, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2531","paramType":"Odds Ratio (OR)","paramValue":"0.82","statisticalComment":"Stratified Analysis","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.04","groupDescription":"Global health status/QoL, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0785","paramType":"Odds Ratio (OR)","paramValue":"0.69","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.03","groupDescription":"Global health status/QoL, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0641","paramType":"Odds Ratio (OR)","paramValue":"0.67","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.80","groupDescription":"Global health status/QoL, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0046","paramType":"Odds Ratio (OR)","paramValue":"0.48","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.37","groupDescription":"Global health status/QoL, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8928","paramType":"Odds Ratio (OR)","paramValue":"0.98","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.74","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6106","paramType":"Odds Ratio (OR)","paramValue":"1.12","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.95","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6159","paramType":"Odds Ratio (OR)","paramValue":"1.15","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.49","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5372","paramType":"Odds Ratio (OR)","paramValue":"1.24","statisticalComment":"Stratified Analysis","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.58","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0845","paramType":"Odds Ratio (OR)","paramValue":"2.22","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"21.56","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1344","paramType":"Odds Ratio (OR)","paramValue":"3.67","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-23.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100.00","groupDescription":"Global health status/QoL, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3173","paramType":"Difference in Proportion of Responders","paramValue":"50.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"1.04","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.92","groupDescription":"Role functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0260","paramType":"Odds Ratio (OR)","paramValue":"1.41","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.37","groupDescription":"Role functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9179","paramType":"Odds Ratio (OR)","paramValue":"1.02","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.53","groupDescription":"Role functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.5820","paramType":"Odds Ratio (OR)","paramValue":"1.10","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","groupDescription":"Role functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9772","paramType":"Odds Ratio (OR)","paramValue":"0.99","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.10","groupDescription":"Role functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1300","paramType":"Odds Ratio (OR)","paramValue":"0.73","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupDescription":"Role functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0990","paramType":"Odds Ratio (OR)","paramValue":"0.66","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.50","groupDescription":"Role functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7133","paramType":"Odds Ratio (OR)","paramValue":"1.07","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.11","groupDescription":"Role functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1384","paramType":"Odds Ratio (OR)","paramValue":"1.38","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.26","groupDescription":"Role functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2895","paramType":"Odds Ratio (OR)","paramValue":"1.33","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.14","groupDescription":"Role functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2221","paramType":"Odds Ratio (OR)","paramValue":"1.55","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"2.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"26.10","groupDescription":"Role functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0005","paramType":"Odds Ratio (OR)","paramValue":"7.37","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"34.56","groupDescription":"Role functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2171","paramType":"Odds Ratio (OR)","paramValue":"3.72","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-46.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"79.82","groupDescription":"Role functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Proportion of Responders","paramValue":"16.67"},{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.48","groupDescription":"Social functioning, Cycle 3 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4647","paramType":"Odds Ratio (OR)","paramValue":"1.11","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.40","groupDescription":"Social functioning, Cycle 5 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7676","paramType":"Odds Ratio (OR)","paramValue":"1.04","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.71","groupDescription":"Social functioning, Cycle 8 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1983","paramType":"Odds Ratio (OR)","paramValue":"1.24","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.44","groupDescription":"Social functioning, Cycle 12 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.9874","paramType":"Odds Ratio (OR)","paramValue":"1.00","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.29","groupDescription":"Social functioning, Cycle 16 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.4716","paramType":"Odds Ratio (OR)","paramValue":"0.86","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupDescription":"Social functioning, Cycle 20 Day 1","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2041","paramType":"Odds Ratio (OR)","paramValue":"0.74","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.45","groupDescription":"Social functioning, Completion of Treatment/ Early Termination Visit","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.7771","paramType":"Odds Ratio (OR)","paramValue":"1.05","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.64","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.45","groupDescription":"Social functioning, Post-Treatment Follow Up 3 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8542","paramType":"Odds Ratio (OR)","paramValue":"0.96","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.50","groupDescription":"Social functioning, Post-Treatment Follow Up 6 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1230","paramType":"Odds Ratio (OR)","paramValue":"1.50","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.34","groupDescription":"Social functioning, Post-Treatment Follow Up 9 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1089","paramType":"Odds Ratio (OR)","paramValue":"1.72","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"1.85","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"18.30","groupDescription":"Social functioning, Post-Treatment Follow Up 12 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0011","paramType":"Odds Ratio (OR)","paramValue":"5.82","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.74","groupDescription":"Social functioning, Post-Treatment Follow Up 18 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.2950","paramType":"Odds Ratio (OR)","paramValue":"2.51","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"-37.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100.00","groupDescription":"Social functioning, Post-Treatment Follow Up 24 Months","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","paramType":"Difference in Proportion of Responders","paramValue":"33.33"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1"},{"groupId":"OG001","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1"},{"groupId":"OG001","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"423"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4"},{"groupId":"OG001","value":"23.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"414"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2"},{"groupId":"OG001","value":"16.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"378"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1"},{"groupId":"OG001","value":"17.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Physical Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"},{"groupId":"OG001","value":"25.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"366"}],"units":"Participants"}],"title":"Physical Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6"},{"groupId":"OG001","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0"},{"groupId":"OG001","value":"25.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8"},{"groupId":"OG001","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4"},{"groupId":"OG001","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Physical Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3"},{"groupId":"OG001","value":"27.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"Role Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7"},{"groupId":"OG001","value":"27.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Role Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1"},{"groupId":"OG001","value":"22.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"401"}],"units":"Participants"}],"title":"Role Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"16.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"title":"Role Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1"},{"groupId":"OG001","value":"15.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"311"}],"units":"Participants"}],"title":"Role Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6"},{"groupId":"OG001","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"233"}],"units":"Participants"}],"title":"Role Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"24.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Role Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9"},{"groupId":"OG001","value":"27.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4"},{"groupId":"OG001","value":"25.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0"},{"groupId":"OG001","value":"26.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7"},{"groupId":"OG001","value":"37.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"31.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Role Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0"},{"groupId":"OG001","value":"31.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"442"}],"units":"Participants"}],"title":"Social Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6"},{"groupId":"OG001","value":"30.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Social Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8"},{"groupId":"OG001","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Social Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9"},{"groupId":"OG001","value":"19.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"Social Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5"},{"groupId":"OG001","value":"17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Social Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2"},{"groupId":"OG001","value":"16.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Social Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2"},{"groupId":"OG001","value":"28.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Social Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5"},{"groupId":"OG001","value":"25.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"30.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6"},{"groupId":"OG001","value":"32.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9"},{"groupId":"OG001","value":"37.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"},{"groupId":"OG001","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Social Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8"},{"groupId":"OG001","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"454"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3"},{"groupId":"OG001","value":"15.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6"},{"groupId":"OG001","value":"12.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"412"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2"},{"groupId":"OG001","value":"13.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2"},{"groupId":"OG001","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5"},{"groupId":"OG001","value":"11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Emotional Functioning, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3"},{"groupId":"OG001","value":"19.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"Emotional Functioning, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7"},{"groupId":"OG001","value":"16.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9"},{"groupId":"OG001","value":"14.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"18.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9"},{"groupId":"OG001","value":"22.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"31.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Emotional Functioning, Post-Treatment Follow Up 24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2"},{"groupId":"OG001","value":"22.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"455"},{"groupId":"OG001","value":"443"}],"units":"Participants"}],"title":"GHS/OoL Function, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1"},{"groupId":"OG001","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"422"}],"units":"Participants"}],"title":"GHS/OoL Function, Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3"},{"groupId":"OG001","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"413"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"GHS/OoL Function, Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6"},{"groupId":"OG001","value":"13.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"title":"GHS/OoL Function, Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3"},{"groupId":"OG001","value":"13.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"333"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"title":"GHS/OoL Function, Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2"},{"groupId":"OG001","value":"11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"GHS/OoL Function, Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"24.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"GHS/OoL Function, Completion of Treatment/ Early Termination Visit"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"},{"groupId":"OG001","value":"22.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"234"},{"groupId":"OG001","value":"236"}],"units":"Participants"}],"title":"GHS/OoL Function, Post-Treatment Follow Up 3 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9"},{"groupId":"OG001","value":"23.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"GHS/OoL Function, Post-Treatment Follow Up 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4"},{"groupId":"OG001","value":"25.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"GHS/OoL Function, Post-Treatment Follow Up 9 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8"},{"groupId":"OG001","value":"34.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"GHS/OoL Function, Post-Treatment Follow Up 12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4"},{"groupId":"OG001","value":"43.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"GHS/OoL Function, Post-Treatment Follow Up 18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"GHS/OoL Function, Post-Treatment Follow Up 24 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"473"},{"groupId":"OG001","value":"473"}],"units":"Participants"}],"description":"Percentage of participants with deterioration in patient-reported function and HRQoL, defined as \\>= 10 points decrease from the baseline score on each of the functional (physical, role, emotional, and social) and GHS/QoL scales of the EORTC QLQ-C30.","groups":[{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab placebo IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab placebo for a total of 22 cycles of atezolizumab placebo and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and placebo for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and placebo for additional 16 cycles.","id":"OG000","title":"Placebo With Paclitaxel, Carboplatin and Bevacizumab"},{"description":"Participants in the primary tumor-reductive surgery group received paclitaxel, carboplatin, atezolizumab intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles, and bevacizumab IV infusion starting with Cycle 2 for a total of 5 cycles, followed by maintenance therapy bevacizumab with atezolizumab for a total of 22 cycles of atezolizumab and 21 cycles of bevacizumab. Participants in the neoadjuvant therapy group received paclitaxel, carboplatin and atezolizumab for 6 cycles and bevacizumab for 4 cycles. Interval surgery will occur between cycles 3 and 4. Each cycle is 21 days long. After 6 cycles, participants started maintenance therapy of bevacizumab and atezolizumab for additional 16 cycles.","id":"OG001","title":"Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab"}],"paramType":"NUMBER","populationDescription":"PRO-evaluable population is defined as patients in the ITT population with a baseline and \\>=1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of treatment/discontinuation (up to approximately 66 weeks), and during follow-up period (up to approximately 60 months). Cycle length=21 days.","title":"Percentage of Participants With Deterioration in Patient-Reported Function and HRQoL - Primary Tumor-Reductive Surgery Group","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}